ArticleThe pharmacogenomics journal2022
Correction to: PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors.
Julia C F Quintanilha, Alessandro Racioppi, Jin Wang, Amy S Etheridge, Stefanie Denning, Carol E Peña, Andrew D Skol, Daniel J Crona, Danyu Lin, Federico Innocenti
Open access · bronzeAbstract readPublished Erratum
In one paragraphArticle in The pharmacogenomics journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 73% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
10 authors at 3 institutions in 1 country.
Julia C F QuintanilhaDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. juquint@email.unc.edu.ORCID http://orcid.org/0000-0001-6908-4474 Alessandro RacioppiDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jin WangDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Amy S EtheridgeDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Stefanie DenningDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Carol E PeñaBayer Health Care Pharmaceuticals, Whippany, NJ, USA.
Andrew D SkolDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
Daniel J CronaDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0003-3742-8863 Danyu LinDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Federico InnocentiDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. federico.innocenti@abbvie.com.ORCID http://orcid.org/0000-0001-9247-979X University of North Carolina at Chapel Hill · USBayer (United States) · USUniversity of Chicago · US
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID34934177
OpenAlexW4200300138
What OpenQuestion holds
Textmetadata
Read underepoch 390